JPRN-UMIN000002748CompletedPhase 4
Response-Guided Interferon Therapy for patients with chronic hepatitis C of the Genotype 1 high viral load: Japanese multi-center, randomized controlled study: (ReGIT-J study) - Response-Guided Interferon Therapy for patients with chronic hepatitis C : Japanese multi-center, randomized controlled study: (ReGIT-J study)
Conditions
Trial Snapshot
- Phase
- Phase 4
- Status
- Completed
- Sponsor
- Hyogo College Of Medicine
- Enrollment
- 300
Study Overview
Brief Summary
No summary available.
Study Design
- Study Type
- Interventional
Eligibility Criteria
- Ages
- ot applicable to ot applicable (—)
- Sex
- All
Inclusion Criteria
- Not provided
Exclusion Criteria
- •1.A pregnant woman, the woman who may have become pregnant, or the woman under breastfeeding 2.The patient who has an anamnesis of hypersensitivity to the ingredient or other nucleoside analogs of this agent (acyclovir, ganciclovir, Bidarabin, etc.) 3.A patient with cardiac disease (myocardial infarction, heart failure, abnormal heart rhythm etc.) with difficult control 4.The patient of abnormal hemoglobin diseases (sarasemia, drepanocytic anemia, etc.) 5.The patient to whom the following renal dysfunction has chronic renal failure or a creatinine clearance by 50mL/min 6.A patient with the patient in serious mental disease states, such as serious depression, suicide ideation, or a suicide attempt, or its anamnesis 7.A critical impaired liver function patient 8.The patient of autoimmune hepatitis 9.The patient who is prescribing Syousaikotou 10.The chronic liver disease patient of others, such as autoimmune hepatitis and alcoholic hepatitis 11.The patient who has an anamnesis of hypersensitivity to the ingredient or other interferon tablets of this agent 12.The patient who has an anamnesis of hypersensitivity to biological preparation, such as a vaccine 13.The patient of liver cirrhosis, hepatic insufficiency, and cancer of liver 14.The patient who meets at least one standard of the following clinical laboratory test result / before a medication start before treatment WBC countLess than 3,000/mm3 neutrophil countLess than 1,500/mm3 PLT countLess than 90,000/mm3 Hemoglobin contentLess than 12g/dl 15.In addition, the patient whom the examination doctor in attendance judged that the participation to an exam is unsuitable
Investigators
Similar Trials
Recruiting
Not Applicable
Efficacy of interferon therapy for recurrence-free and overall survival after curative radiofrequency ablation for HCV-related hepatocellular carcinoma.hepatocellular carcinomaJPRN-UMIN000006761Kyoundo hospital50
Recruiting
Phase 3
The effect of interferon on the treatment of covid19 patientsIRCT20160118026097N3Ghoum University of Medical Sciences60
Recruiting
Phase 3
Trial of novel combined therapy between interferon and hyperlipidemia for chronic hepatitis C patientschronic hepatitis type CJPRN-UMIN000005598Kyoto University Graduate School of Medicine Center for Genomic Medicine100
Active, not recruiting
Not Applicable
Multiferon treatment of non-responders to peg-IFN alfa plus ribavirin standard of care treatment - a study of the early viral kinetics during the initial 12 weeks treatment. - IFN-Multiferon08HCV RNA response to a multivalent IFN (Multiferon 6 MU q.d. + ribavirin standard dosed) in prior non-responders to SOC (peg-IFN + ribavirin) during treatment the initial 12 weeks. Results of HCV RNA decline weeks 4 and 12 with SOC and this new treatment will be compared.EUCTR2008-007104-28-SEKarolinska Universitetssjukhuset20
Recruiting
Not Applicable
Efficacy and safety of interferon-free treatment in patients with chronic hepatitis Cchronic hepatitis CJPRN-UMIN000037575Osaka university1,000